All In Biotech

Drug Trial Radar · NCT04069689

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

A Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to Assess Safety and Pharmacokinetics of Escalating Single and Multiple Oral Doses of EPX-100 in Fasting Healthy Subjects and Following a High-Fat Meal

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 29, 2019

Primary completion

Nov 27, 2019

Study completion Nov 27, 2019

Sponsor

Lead sponsor
EpygenixIndustry
Sponsor type
Industry
First posted
Aug 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a placebo-controlled, double-blind, 2-period study in 3 sequential groups of 8 healthy subjects each. The safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 will be assessed in fasting healthy subjects and following a high-fat meal.

Conditions

  • Dravet Syndrome

Interventions

  • EPX-100 (Clemizole Hydrochloride)Drug

    EPX-100 (Clemizole Hydrochloride)

  • PlacebosDrug

    Placebo to match EPX-100

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs)Time frame: 21 days
  2. Serial ECGs - QTcF IntervalTime frame: 21 days
  3. Physical Examinations Including Actual Body WeightTime frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TKL Research

    Fair Lawn, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.